ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -66 مورد

Albendazole: Pediatric drug information

Albendazole: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Albendazole: Drug information" and "Albendazole: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Albenza [DSC]
Therapeutic Category
  • Anthelmintic
Dosing: Pediatric
Ascariasis [intestinal roundworm]

Ascariasis (intestinal roundworm): Limited data available:

Children <2 years: Oral: 200 to 400 mg as a single dose (Ref).

Children ≥2 years and Adolescents: Oral: 400 mg as a single dose (Ref).

Baylisascaris procyonis, postexposure prophylaxis and treatment

Baylisascaris procyonis (raccoon roundworm), postexposure prophylaxis and treatment: Limited data available:

Children and Adolescents: Oral: 20 to 50 mg/kg/day in a single dose or 2 divided doses or 400 mg twice daily for 10 to 20 days. Longer duration (eg, 3 to 4 weeks) has also been described. Initiate as soon as possible after potential exposure (ideally within 3 days) to prevent clinical disease in any child at risk (eg, ingestion of raccoon stool or contaminated soil) (Ref).

Capillariasis

Capillariasis: Limited data available: Children and Adolescents: Oral: 400 mg once daily for at least 10 days (Ref).

Enterobiasis [pinworm]

Enterobiasis (pinworm): Limited data available:

Children <2 years: Oral: 200 mg as a single dose; may repeat in 2 weeks (Ref).

Children ≥2 years and Adolescents: Oral: 400 mg as a single dose; repeat in 2 weeks (Ref).

Giardiasis

Giardiasis (Giardia duodenalis) (alternative therapy): Limited data available: Children ≥2 years and Adolescents: Oral: 10 to 15 mg/kg/dose once daily for 5 to 10 days; maximum dose: 400 mg/dose (Ref).

Gnathostomiasis, cutaneous

Gnathostomiasis, cutaneous:

Children and Adolescents: Limited data available: Oral: 400 mg twice daily for 21 days (Ref).

Hookworm-related cutaneous larva migrans

Hookworm-related cutaneous larva migrans (Ancylostoma braziliense, Ancylostoma caninum, Ancylostoma ceylanicum, Uncinaria stenocephala):

Infants ≥2 months and Children ≤2 years: Very limited data available: Oral: 15 mg/kg/dose once daily for 3 days; maximum dose: 200 mg/dose. Dosing based on case reports; some patients ≥8 months of age received fixed doses of 200 mg/dose and in one case the dosing was split into two divided doses (Ref).

Children >2 years and Adolescents: Limited data available: Oral: 15 mg/kg/dose once daily for 3 days; maximum dose: 400 mg/dose (Ref). Fixed dosing of 400 mg once daily for 3 days has also been recommended (Ref).

Hookworms, human

Hookworms, human (Ancylostoma duodenale or N. americanus) :

Infants ≥3 months: Very limited data available: Oral: 200 mg as a single dose. Dosing based on two cases (patient #1: age: 12 weeks, weight: 4.2 kg; and patient #2: age: 8 months, weight: 5.8 kg) of exclusively breastfed infants who showed clinical improvement after single-dose albendazole therapy (Ref).

Children <2 years: Limited data available: Oral: 200 to 400 mg as a single dose; may repeat in 3 weeks if needed (Ref).

Children ≥2 years and Adolescents: Limited data available: Oral: 400 mg as a single dose; may repeat in 3 weeks if needed (Ref).

Hydatid disease [Echinococcus granulosus, dog tapeworm]

Hydatid disease (E. granulosus, dog tapeworm): Children and Adolescents: Oral: 5 to 7.5 mg/kg/dose twice daily for 1 to 6 months; maximum dose: 400 mg/dose (Ref).

Liver flukes

Liver flukes (Clonorchiasis or Opisthorchiasis) (alternative therapy): Limited data available: Children and Adolescents: Oral: 10 mg/kg/dose once daily for 7 days (Ref).

Loiasis

Loiasis: Children and Adolescents: Limited data available: Oral: 200 mg twice daily for 21 days (Ref).

Microsporidia infection

Microsporidia infection: Limited data available: Note: Limited or no efficacy against Enterocytozoon spp. (eg, Enterocytozoon bieneusi) or Vittaforma corneae (Ref).

Children and Adolescents: Oral: 7.5 mg/kg/dose twice daily; maximum dose: 400 mg/dose (Ref). Duration of therapy is not well established but should be individualized based on immune status, site of infection (localized or disseminated), and clinical response; 2 to 4 weeks has been suggested, though 7 days of therapy may be adequate in immunocompetent patients with infection limited to the GI tract. In patients with HIV, continue until resolution of signs and symptoms and sustained immune reconstitution (>6 months at CDC immunologic category 1 or 2) after antiretroviral therapy initiation (Ref).

Neurocysticercosis, parenchymal disease

Neurocysticercosis (T. solium, pork tapeworm), parenchymal disease: Note: Patients should receive concurrent corticosteroid for the first week of albendazole therapy and antiseizure medication therapy as required. If >2 viable cysts present, combination therapy with praziquantel is recommended (Ref).

Children and Adolescents: Oral: 7.5 mg/kg/dose twice daily for 10 to 14 days; maximum dose: 600 mg/dose. Treatment for up to 30 days has also been recommended (Ref).

Strongyloidiasis

Strongyloidiasis (S. stercoralis) (alternative agent): Limited data available: Children and Adolescents: Oral: 400 mg twice daily for 7 days; patients with hyperinfection and disseminated disease may need prolonged or repeated treatment (eg, daily treatment until stool and/or sputum exams are negative for 2 weeks) (Ref).

Toxocariasis

Toxocariasis: Limited data available:

Children and Adolescents: Oral: 400 mg twice daily. Treatment for 5 days is recommended; however, optimal treatment duration unknown. Treatment for ocular larva migrans has been reported for up to 2 to 4 weeks (Ref).

Trichinellosis

Trichinellosis (Trichinosis): Limited data available: Children and Adolescents: Oral: 400 mg twice daily for 8 to 14 days (Ref).

Trichuriasis [whipworm]

Trichuriasis (whipworm): Limited data available: Children and Adolescents: Oral: 400 mg once daily for 3 days; heavy infestations may be treated for 5 to 7 days (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, the need for adjustment not likely since albendazole is primarily eliminated by hepatic metabolism.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; consider discontinuing therapy if hepatic enzymes increase to twice the ULN while on therapy based on patient clinical status.

Dosing: Adult

(For additional information see "Albendazole: Drug information")

Dosage guidance:

Clinical considerations: For systemic infections, coadministration with a high-fat meal is recommended to increase absorption (Ref); for intraluminal infections, administration on an empty stomach may be appropriate (Ref).

Ascariasis, intestinal

Ascariasis, intestinal (roundworm) (off-label use):

Note: For patients with complications (eg, intestinal obstruction, acute cholangitis), initiate therapy after resolution of acute symptoms (Ref).

Oral: 400 mg as a single dose (Ref).

Capillariasis

Capillariasis (off-label use): Oral: 400 mg once or twice daily for ≥10 to 30 days (Ref).

Cutaneous larva migrans

Cutaneous larva migrans (dog and cat hookworm) (off-label use): Oral: 400 mg once daily for 3 days (Ref); for patients with extensive or multiple lesions, may extend therapy to 7 days (Ref).

Echinococcosis

Echinococcosis ( dog tapeworm):

Alveolar echinococcosis (E. multilocularis) (off-label use):

Note: Surgical resection is the primary approach to treatment; antiparasitic therapy is recommended postoperatively to reduce relapse or as palliative therapy when surgery is unfeasible (Ref).

Oral: 15 mg/kg/day (maximum: 800 mg/day) in 2 divided doses. Optimal duration is uncertain; give for ≥2 years to indefinitely, depending on extent of surgical resection (Ref).

Cystic echinococcosis (E. granulosus, also known as hydatid disease):

Note: For cysts with diameter >5 cm or multiple compartments (WHO stage CE2 or CE3b), use in combination with surgical resection or percutaneous treatment; initiate albendazole ≥1 day preoperatively (Ref).

Oral: 15 mg/kg/day (maximum: 800 mg/day) in 2 divided doses. Optimal duration uncertain; give for 1 to 6 months based on clinical factors (Ref).

Giardiasis

Giardiasis (alternative agent) (off-label use):

Note: Treatment of asymptomatic infection is warranted in selected settings to prevent transmission to vulnerable populations (eg, group settings, household contacts of immunocompromised or pregnant individuals, food handlers) (Ref).

Oral: 400 mg once daily for 5 days (Ref). For patients with refractory infection after repeated courses of preferred agents, some experts suggest albendazole 400 mg once daily in combination with metronidazole for 5 to 7 days (Ref).

Gnathostomiasis, cutaneous

Gnathostomiasis, cutaneous (off-label use):

Note: Not recommended for CNS disease due to inflammatory response from dying larvae (Ref).

Oral: 400 mg twice daily for 21 days (Ref).

Hookworm infection

Hookworm infection (Ancylostoma duodenale or Necator americanus) (off-label use): Oral: 400 mg as a single dose (Ref); limited data suggest improved microbiologic cure with higher doses (800 mg as a single dose or 400 mg once daily for 3 days) (Ref).

Intestinal tapeworm infection

Intestinal tapeworm infection (Taeniasis) (alternative agent) (off-label use): Oral: 400 mg once daily for 3 days (Ref).

Liver fluke infection

Liver fluke infection (Clonorchis sinensis or Opisthorchis viverrine) (alternative agent) (off-label use):Oral: 10 mg/kg/day for 7 days (maximum dose: 400 mg twice daily) (Ref).

Microsporidiosis

Microsporidiosis (off-label use):

Note: Albendazole is not recommended for Enterocytozoon bieneusi or Vittaforma corneae because of limited efficacy (Ref).

Immunocompromised (including patients with HIV):

Disseminated or intestinal infection: Oral: 400 mg twice daily for ≥14 to 21 days (Ref); for patients with HIV, continue until CD4 count >200 cells/mm3 for ≥3 months after initiation of antiretroviral therapy (Ref). For disseminated disease due to Trachipleistophora or Anncaliia, use in combination with itraconazole (Ref).

Ocular infection: Oral: 400 mg twice daily in combination with topical fumagillin until CD4 count >200 cells/mm3 and ocular symptoms resolve (Ref).

Immunocompetent:

Extraintestinal infection: Oral: 400 mg twice daily for 7 to 14 days (Ref); some experts give for up to 3 weeks for severe or slowly resolving symptoms (Ref). For ocular infection, use in combination with topical fumagillin (Ref).

Intestinal (Encephalitozoon intestinalis) infection: Oral: 400 mg twice daily (Ref) for 7 to 14 days (Ref).

Neurocysticercosis, parenchymal disease

Neurocysticercosis, parenchymal disease ( Taenia solium , pork tapeworm):

Note: For viable or degenerating noncalcified cysts only; avoid with untreated hydrocephalus, diffuse cerebral edema with multiple cysts (ie, cysticercal encephalitis), or ocular lesions because of risks from worsening inflammation. Manage in consultation with an expert in neurocysticercosis (Ref).

Oral: 15 mg/kg/day in 2 divided doses (maximum: 1.2 g/day) in combination with adjunctive glucocorticoids; start >1 day after glucocorticoid initiation. For patients with >2 viable cysts present, use in combination with praziquantel (Ref). Duration of antiparasitic therapy is 7 to 14 days (Ref). For persistent viable lesions on 6-month follow-up imaging, may re-treat with same regimen as initial therapy (Ref).

Pinworm infection

Pinworm infection (Enterobiasis) (off-label use): Oral: 400 mg as a single dose; repeat dose in 2 weeks (Ref).

Toxocariasis

Toxocariasis (off-label use):

Ocular larva migrans with sight-threatening ocular inflammation:Optimal dose and duration are not well-defined: Oral: 400 mg twice daily for 2 weeks (Ref); use in combination with glucocorticoids (Ref).

Visceral larva migrans, moderate to severe: Oral: 400 mg twice daily for 5 days (Ref). For individuals in East Asia, some experts favor a longer duration (eg, 4 weeks) (Ref). For severe infection, use in combination with glucocorticoids (Ref).

Trichinellosis

Trichinellosis (off-label use): Oral: 400 mg twice daily for 8 to 14 days; for severe symptoms, may be used in combination with glucocorticoids (Ref).

Trichostrongylosis

Trichostrongylosis (off-label use): Oral: 400 mg as a single dose (Ref).

Whipworm infection

Whipworm infection (Trichuriasis) (off-label use): Oral: 400 mg once daily for 3 days alone or in combination with ivermectin (Ref); monotherapy is considered an alternative as it associated with lower efficacy (Ref). For resource-limited settings, may use single-dose combination therapy (400 mg as a single dose in combination with single-dose ivermectin) (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Oral: No dosage adjustment necessary for any degree of kidney impairment (<1% urinary excretion of active metabolite) (Ref).

Hemodialysis, intermittent (thrice weekly): Oral: Dialyzability unknown: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Oral: Dialyzability unknown: No dosage adjustment necessary (Ref).

CRRT: Oral: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in manufacturer's labeling. However, patients with underlying liver disease may be more at risk for adverse effects.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (neurocysticercosis: 11%; hydatid: 1%)

Hepatic: Increased liver enzymes (hydatid: 16%; neurocysticercosis: <1%)

1% to 10%:

Central nervous system: Increased intracranial pressure (≤2%), dizziness (≤1%), vertigo (≤1%), meningism (1%)

Dermatologic: Alopecia (<1% to 2%)

Gastrointestinal: Abdominal pain (≤6%), nausea and vomiting (4% to 6%)

Miscellaneous: Fever (≤1%)

<1%, postmarketing, and/or case reports: Acute hepatic failure, acute renal failure, agranulocytosis, aplastic anemia, erythema multiforme, granulocytopenia, hepatitis, hypersensitivity reaction, leukopenia, neutropenia, pancytopenia, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria

Contraindications

Hypersensitivity to albendazole, benzimidazoles, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia have occurred leading to fatalities (rare); use with caution in patients with hepatic impairment (more susceptible to hematologic toxicity). Discontinue therapy in all patients who develop clinically significant decreases in blood cell counts.

• Transaminase elevations: Reversible elevations in hepatic enzymes have been reported. Patients with abnormal LFTs and hepatic echinococcosis are at an increased risk of hepatotoxicity. Discontinue therapy if LFT elevations are >2 times the upper limit of normal; may consider restarting treatment (with frequent monitoring of LFTs) when hepatic enzymes return to pretreatment values. Discontinue therapy if hepatic enzymes are significantly increased.

Disease-related concerns:

• Neurocysticercosis: Appropriate use: Antiparasitic therapy may worsen symptoms of neurocysticercosis by inducing an inflammatory response; adjunctive corticosteroid therapy should be started before initiation of albendazole. Antiparasitic therapy should not be initiated in patients with untreated hydrocephalus, calcified lesions, or cysticercal encephalitis. Perform funduscopic exam prior to initiation of antiparasitic therapy to exclude intraocular cysticerci; antiparasitic therapy may lead to blindness in some cases with unsuspected intraocular parasites (IDSA/ASTMH [White 2018]).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Albenza: 200 mg [DSC]

Generic: 200 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Albendazole Oral)

200 mg (per each): $18.00 - $276.65

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Pediatric

Oral: Administer with a high-fat meal to increase absorption. For patients who have difficulty swallowing whole tablets, tablet may be crushed or chewed and swallowed with a drink of water.

Administration: Adult

Oral: For systemic infection, coadministration with a high-fat meal is recommended to increase absorption (Ref); for intraluminal infection, administration on an empty stomach may be appropriate (Ref). If patients have difficulty swallowing, tablets may be crushed or chewed, then swallowed with a drink of water.

Storage/Stability

Store between 20°C and 25°C (68°F to 77°F)

Use

Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of Taenia solium (pork tapeworm) and treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of Echinococcus granulosus (dog tapeworm) (FDA approved in pediatric patients [age not specified] and adults); has also been used in the treatment of zoonotic hookworms (cutaneous larva migrans), ascariasis (intestinal roundworm), Baylisascaris procyonis (raccoon roundworm), capillariasis, liver flukes (Clonorchis sinensis and Opisthorchis viverrini), enterobiasis (pinworm), filariasis (Wuchereria bancroft), giardiasis, microsporidiosis, Necator americanus (hookworm), Strongyloides stercoralis, trichinellosis (trichinosis), Trichuris trichiura (whipworm), and toxocariasis (ocular larva migrans, visceral larva migrans).

Medication Safety Issues
Sound-alike/look-alike issues:

Albenza may be confused with Aplenzin, Relenza.

International issues:

Albenza [US] may be confused with Avanza brand name for mirtazapine [Australia].

Metabolism/Transport Effects

Substrate of CYP1A2 (Minor), CYP3A4 (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

CarBAMazepine: May decrease active metabolite exposure of Albendazole. Risk C: Monitor

Grapefruit Juice: May increase active metabolite exposure of Albendazole. Specifically, concentrations of albendazole sulfate may be increased. Risk C: Monitor

Nirmatrelvir and Ritonavir: May decrease serum concentration of Albendazole. Risk C: Monitor

PHENobarbital: May decrease active metabolite exposure of Albendazole. Risk C: Monitor

Phenytoin: May decrease active metabolite exposure of Albendazole. Risk C: Monitor

Ritonavir: May decrease serum concentration of Albendazole. Risk C: Monitor

Food Interactions

Albendazole serum levels may be increased if taken with a fatty meal (increases the oral bioavailability by up to 5 times). Management: Should be administered with a high-fat meal when treating systemic infections.

Reproductive Considerations

Evaluate pregnancy status prior to use; pregnancy testing is recommended in patients who could become pregnant (CDC 2019a; Persichino 2018). Effective contraception is recommended during chronic therapy (Persichino 2018) and for 1 month after the last dose (per the manufacturer).

The World Health Organization recommends preventive therapy with a benzimidazole, such as albendazole, for patients who could become pregnant who live in areas where the baseline prevalence of soil-transmitted helminth infections is ≥20% (WHO 2017).

Pregnancy Considerations

Outcome data following first trimester use of albendazole are limited (Gyorkos 2019; Lau 2020). Most pregnancy outcome data are available from studies using a single dose of albendazole administered to patients during the second or third trimester (Gyorkos 2019; Lau 2020; Mofid 2017; Salam 2021). However, case reports are also available following longer term treatment of hydatid disease (Auer 1994; Bhattacharyya 2013; Gul 2023; Llanos 2020; Pallua 2010; Sahin 2021).

Untreated soil-transmitted helminth infections during pregnancy are associated with adverse maternal outcomes (eg, maternal iron deficiency anemia, impaired nutrient absorption) (WHO 2017).

Use of albendazole during the first trimester of pregnancy is not recommended (HHS [OI Adult 2024]; IDSA/ASTMH [White 2018]; WHO 1996; WHO 2017). Pregnant patients with neurocysticercosis should be treated for symptoms (eg, increased intracranial pressure, seizures) the same as nonpregnant patients; however, antihelminthic therapy with albendazole can be deferred until after delivery (IDSA/ASTMH [White 2018]). Albendazole should not be used for the treatment of microsporidiosis in HIV-infected pregnant patients during the first trimester; use later in pregnancy may be considered when the benefits outweigh potential risks (HHS [OI Adult 2024]; White 2018). The WHO also recommends treatment of soil-transmitted helminthiases (such as hookworm) in pregnant patients after the first trimester (WHO 1996). Pregnant patients arriving as refugees from specific countries should not be given albendazole for the presumptive treatment of intestinal parasites prior to arrival in the United States; presumptive treatment can be deferred until arrival (CDC 2019a).

Monitoring Parameters

Monitor LFTs and CBC at baseline and every 2 weeks during therapy (more frequently for patients with liver disease); pregnancy test in patients who can become pregnant.

Mechanism of Action

Active metabolite, albendazole sulfoxide, causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired, and desecratory substances accumulate intracellulary. ATP production decreases causing energy depletion, immobilization, and worm death.

Pharmacokinetics (Adult Data Unless Noted)

Note: In pediatric patients (6 to 13 years), pharmacokinetic values were reported to be similar to adult data.

Absorption: Poor from the GI tract; may increase up to 5 times when administered with a fatty meal.

Distribution: Widely distributed throughout the body including urine, bile, liver, cyst wall, cyst fluid, and CSF.

Protein binding: 70%.

Metabolism: Hepatic; extensive first-pass effect; pathways include rapid sulfoxidation to active metabolite (albendazole sulfoxide [major]), hydrolysis, and oxidation.

Half-life elimination: 8 to 12 hours (albendazole sulfoxide).

Time to peak, serum: 2 to 5 hours for the metabolite.

Excretion: Urine (<1% as active metabolite); feces.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Systemic availability, rate of absorption, and the elimination half-life of albendazole sulfoxide are increased in patients with extrahepatic obstruction.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Albenda | Zentel;
  • (AR) Argentina: Nematel | Vastus | Vermicet | Vermizole;
  • (AT) Austria: Eskazole;
  • (BD) Bangladesh: Abentel | Adze | Al | Al-Ds | Alba | Albazole | Alben | Albenda | Albizol | Alda ds | Alentin | Almex | Almin | Alzed | Alzen | Alzol | Biben | Chuben | Eben-DS | Estazol | Kiltel | Luban | Monoben | Qben ds | Sintel | Triben | Vermid | Zoben;
  • (BF) Burkina Faso: Alben | Albendazole tm | Albentox | Albizol | Alzol | Calben | G abzole | Licdazol | Q worm | Verzil | Verzol | Zentel;
  • (BG) Bulgaria: Zentel;
  • (BR) Brazil: Albel | Albendal | Albendazol | Albendrox | Albentel | Albenzonil | Alib | Alzoben | Benzol | Mebenix | Monozol | Neo bendazol | Parazol | Totelmin | Verdazol | Vermiclase | Vermital | Zolben | Zoldan;
  • (CI) Côte d'Ivoire: Abz | Alben | Albentox | Albex | Albizol | Asbenzol | Azole | Bendex | G abzole | Lyben | Mezol | Parazol | Saniver | Veriben | Zaben | Zentel | Zobend | Zobenol;
  • (CL) Chile: Zentel;
  • (CN) China: Abentel | Zentel;
  • (CO) Colombia: Alben-trex | Albendazol | Albendazol mk | Aldrizol | Almezol | Amezolin | Analon | Ascarzol | Ciclopar | Crysthoidex | Elipar | Famidox | Finapar | Helminzol | Killary | Kyllary | Labendazol | Lisipar | Maxpar | Obedozol | Oxofor | Rotopar | Seldem | Suifazol | Targan | Zentel | Zimpar | Zopirack;
  • (CZ) Czech Republic: Albendazol vim spectrum | Zentel;
  • (DE) Germany: Eskazole;
  • (DO) Dominican Republic: Alben | Albendazol | Albendazol Calox | Albendazol iberofarmaco | Albenzol | Aldamin | Aldezol | Alzol | Apardu | Avadyl | Conssel | Corcen | E.P.E | Ethizol | Fradazol | Kilpar | Krip | Oxarmin | Quizol | Suifazol | Tiroben | Uniben | Unizol | Vermintel | Xadem | Zentel | Zooid;
  • (EC) Ecuador: Al | Albendazol | Albendazol Genfar | Albendazol mk | Albendazol nifa | Albenstar | Ascarol | Fagol | H.G. Alben | Italbenzol | Librabendazol | Rotopar | Tazep | Zentel;
  • (EE) Estonia: Albendazol | Albenza | Andazol | Eskazole;
  • (EG) Egypt: Alzental | Antizole | Vermizole;
  • (ES) Spain: Eskazole;
  • (ET) Ethiopia: Corzole | Helmadol | Nubend | Zestaval;
  • (FR) France: Albendazole Dci | Eskazole | Zentel;
  • (GB) United Kingdom: Eskazole;
  • (GR) Greece: Eskazole | Zentel;
  • (HU) Hungary: Albendazol phama vim | Zentel;
  • (ID) Indonesia: Albendazol | Helben | Zentel;
  • (IE) Ireland: Eskazole | Zentel;
  • (IL) Israel: Eskazole;
  • (IN) India: Abd | Abide | Abwal | Abz | Acizole | Al | Alb | Alba | Albact | Albazole | Alben | Albendol | Albenum | Albest | Albezole | Albol | Albrodo | Albus | Aldezole | Alford | All-in-1 | Alminth | Altec | Alzad | Anoworm | Bandy | Be-dol | Ben | Bend | Bendacid | Benrod | Bentel | Benz | Benzol | Beworm | Biwom | Cidazole | Curezole | Dehel | Dispel | E-worm | Ejectil | Ejectil p | Elben | Elbend | Elbenol | Eldoben | Elminex | Emanthal | Enbenol | Eraworm | Gekare | Helmex | Krumex | Lyben | Mahabend | Mediminth | Milibend | Morband | Neomin | Nopar | Noworm | Odal | Olworm | Omnitel | Panamint | Pentacid | Pentanil | Saf-a | Sanzole | Sidose | Sp worm | Syband | Thelmin | Tiobend | Toko | Ulben | Vanke | Verban | Vermitel | Vormout | Womiban | Wormfix | Wormin-a | Wormitel | Wormpel | Wormtab | Wornil | Xenda | Xenith | Xeroworm AD | Zelbend | Zentel | Zondal | Zybend;
  • (IT) Italy: Zentel;
  • (JO) Jordan: Cystazole;
  • (JP) Japan: Eskazole;
  • (KE) Kenya: Abz | Albasol | Albemed | Alben | Albendol | Albenipro | Alphin ds | Altoa | Azole | Benaworm | Bendex | Elyzole | G abzole | Nubend | Tanzol | Wombit | Womiban | Wooban | Wormpel | Zeben;
  • (KR) Korea, Republic of: Alben | Alben free zole | Albenda | Albendazole daewoong | Albentel | Albenzole | Alberin | Albi | Albicel | Alcandazole | Allbacom | Allbis | Allis | Allssak | Allzental | Alnazol | Alpina | Alpon | Alssak | Alzental | Alzole | Boryung albendazole | Ckd albendazole | Dazole | Dongkoo albendazole | Genitel | Iksu albenzole | Ilyangbio albendazole | Incom | Jeil albendazole | Jenacom | Jr albendazole | Kebendazole | Kwangdong albendazole | Moazol | Moazole | Neobenzole | Olbis | Onetel | Orwon | Ovis | Rallybenda | Shuben | Suben | Windazole | Wonazole | Zentalon | Zentazole | Zentel | Zentrax;
  • (KW) Kuwait: Albenda;
  • (LB) Lebanon: Albenda | Andazol | Bendax | Zentel;
  • (LT) Lithuania: Albendazol | Andazol | Duador | Eskazole | Zentel;
  • (LV) Latvia: Andazol | Duador | Eskazol | Eskazole | Zentel;
  • (MA) Morocco: Azole | Verzol | Zentel;
  • (MX) Mexico: Albendazol | Albendazol bioresearch | Albendazol gi prot | Albendazol Hormona | Albensil | Aldamin | Bendapar | Bradelmin | Bruzol | Buxol | Dazocan | Entoplus | Eskazole | Flatezol | Gascop | Helmison s | Kolexan | Loveral | Lurdex | Olbendital | Vermilan | Vermin-plus | Vermisen | Xermixil | Zenaxin | Zentel;
  • (MY) Malaysia: Albendol | Denzol | Thelban | Vemizol | Zendal | Zentel | Zoben;
  • (NG) Nigeria: Albe f albendazole | Albemed | Antel | Aphazole | Ascantel | Avis | Balzole | Chemtel | Cibendazole | Clarion albendazole | Cystazole | Danzel | Expezol | G abzole | Greatlight albendazole | Jekzol | Krisdazole | Lordazole | Marco | Nci albendazole | Sam albendazole | Synbate | Tamar & pharez albendazole | Ugolife albendazole | Ultiworm | Wormidan | Xtal | Zarra | Zentel | Zestazole | Zolat | Zyroben | Zzatab;
  • (NL) Netherlands: Eskazole;
  • (NO) Norway: Eskazole | Zentel;
  • (PE) Peru: Alben | Albendaken | Albendazol | Cental | Ceprazol | Parasitel | Zentel;
  • (PH) Philippines: Aldazol | Zentel;
  • (PK) Pakistan: Alba | Albazole | Alben | Albendo | Alenda | Aliz | Alovac | Alza | Benda | Desite | Larex | Nenzole | Verid | Worcyt | Wormed | Wormgo | Wormocid | Xedol | Zavic | Zentel | Zentmaf | Zepar;
  • (PL) Poland: Zentel;
  • (PR) Puerto Rico: Albenza;
  • (PT) Portugal: Zentel;
  • (PY) Paraguay: Albendazol prosalud | Aterosol | Daxol plus | Lesmin a | Pantex;
  • (QA) Qatar: Albenda | Andazol | Zentel;
  • (RO) Romania: Albendazol lph | Albendazol vim spectrum | Albendol | Duador | Eskazole | Vermigal novo | Zentel;
  • (RU) Russian Federation: Gelmodol vm | Nemozol;
  • (SA) Saudi Arabia: Albenda | Cystazole | Vermizole;
  • (SG) Singapore: Alzental | Zentel;
  • (SI) Slovenia: Dalben | Eskazole | Zentel;
  • (SK) Slovakia: Zentel;
  • (SL) Sierra Leone: Albezol | Veetel | Welworm | Wormzap | Zeben | Zentel | Zolat;
  • (SR) Suriname: Albendazole mk | Bendex | Dazocan | Zentel;
  • (TH) Thailand: Albatel | Albega | Albemed | Alben | Alben Hero | Albenda | Albenz | Albezol | Aldazole | Alfuca | Alzol | Antheda | Anthel | Azil | Benvatel | Benyad | Enmed | Erasit | Falben | Fatel | Gendazel | Goose Ben | Labenda | Leo 400 | Manozide | Medazde | Mesin | Pipalben | Q worm | San San | Startel | Vermixide | Vetoben | Zalben | Zeben | Zela;
  • (TN) Tunisia: Nemacest | Zentel;
  • (TR) Turkey: Andazol;
  • (TW) Taiwan: Zentel;
  • (UA) Ukraine: Albela | Albendazole pharmex | Aldazol | Nemozol;
  • (UG) Uganda: Albasol | Alzol | Bendas | D worm | Elyzole | Finazol | Vermikil | Verzol | Wormaid | Zeben | Zepar;
  • (UY) Uruguay: Helmiben;
  • (VE) Venezuela, Bolivarian Republic of: Albendazol | Albendazol mf | Albicar | Bevindazol | Helal | Nadoxin | Sostril | Vendazol | Zentel;
  • (VN) Viet Nam: Albenca | Farica | Larzole | Mekozetel | Vinfuca;
  • (ZA) South Africa: Bendex | Wormadole | Zentel;
  • (ZM) Zambia: Alben | G abzole | Nubend | Tanzol | Unibazole | Wormin-a | Zentel;
  • (ZW) Zimbabwe: Abz | Anthel
  1. Albendazole tablets [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals Inc; November 2022.
  2. Albenza (albendazole) tablets [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; September 2019.
  3. Abdel-tawab AM, Bradley M, Ghazaly EA, et al, "Albendazole and its Metabolites in the Breast Milk of Lactating Women Following a Single Oral Dose of Albendazole," Br J Clin Pharmacol, 2009, 68(5):737-42. [PubMed 19916998]
  4. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  5. Auer H, Kollaritsch H, Jüptner J, Aspöck H. Albendazole and pregnancy. Appl Parasitol. 1994;35(2):146-147. [PubMed 8087155]
  6. Baird RA, Wiebe S, Zunt JR, et al, “Evidence-Based Guideline: Treatment of Parenchymal Neurocysticercosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology,” Neurology, 2013, 80(15):1424-9. [PubMed 23568997]
  7. Barisani-Asenbauer T, Maca SM, Hauff W, et al. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Ther. 2001;17(3):287-294. doi: 10.1089/108076801750295317. [PubMed 11436948]
  8. Bartelt LA. Giardiasis: treatment and prevention. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed June 28, 2024.
  9. Bethony J, Brooker S, Albonico M, et al, “Soil-Transmitted Helminth Infections: Ascariasis, Trichuriasis, and Hookworm,” Lancet, 2006, 367(9521):1521-32. [PubMed 16679166]
  10. Bhatia V, Das MK, Kumar P, Arora NK. Infantile hookworm disease. Indian Pediatr. 2010;47(2):190-192. [PubMed 20228435]
  11. Bhattacharyya SK, Bhattacharya S, Alam H, Patua B, Chattopadhyay P. Dilemmas encountered while dealing a pregnancy complicated by pelvic Hydatid disease. Arch Gynecol Obstet. 2013;288(5):965-966. [PubMed 23625356]
  12. Black MD, Grove DI, Butcher AR, Warren LJ. Cutaneous larva migrans in infants in the Adelaide Hills. Australas J Dermatol. 2010;51(4):281-284. [PubMed 21198527]
  13. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pediatric Antimicrobial Therapy. 29th ed. American Academy of Pediatrics; 2023.
  14. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16. doi:10.1016/j.actatropica.2009.11.001 [PubMed 19931502]
  15. Brunetti E, White AC Jr. Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am. 2012;26(2):421-435. doi:10.1016/j.idc.2012.02.001 [PubMed 22632647]
  16. Cañete R, Rodríguez P, Mesa L, et al. Albendazole versus metronidazole in the treatment of adult giardiasis: a randomized, double-blind, clinical trial. Curr Med Res Opin. 2012;28(1):149-154. doi:10.1185/03007995.2011.637915 [PubMed 22114904]
  17. Centers for Disease Control and Prevention (CDC) parasite website. https://www.cdc.gov/parasites/index.html. Accessed November 11, 2016.
  18. Centers for Disease Control and Prevention (CDC). Parasites - Cysticercosis. Available at http://www.cdc.gov/parasites/cysticercosis/health_professionals/index.html#drugs. Updated April 2016.
  19. Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep. 2009;58(RR-11):1-166. [PubMed 19730409]
  20. Centers for Disease Control and Prevention (CDC). Guidelines for overseas presumptive treatment of strongyloidiasis, schistosomiasis, and soil-transmitted helminth infections for refugees resettling to the United States. https://www.cdc.gov/immigrant-refugee-health/hcp/overseas-guidance/intestinal-parasite-guidelines.html. Updated February 2019a.
  21. Centers for Disease Control and Prevention (CDC). Parasites. https://www.cdc.gov/parasites/index.html. Updated August 19, 2022. Accessed August 31, 2022.
  22. Centers for Disease Control and Prevention (CDC). Parasites - Ascariasis. https://www.cdc.gov/parasites/ascariasis/health_professionals/index.html. Updated May 20, 2020a. Accessed February 29, 2024.
  23. Centers for Disease Control and Prevention (CDC). Parasites - Baylisascaris infection. https://www.cdc.gov/parasites/baylisascaris/health_professionals/index.html. Updated August 28, 2019b. Accessed October 2, 2023.
  24. Centers for Disease Control and Prevention (CDC). Parasites - Capillariasis (also known as Capillaria infection). https://www.cdc.gov/parasites/capillaria/health_professionals/index.html. Updated May 20, 2020b. Accessed March 6, 2024.
  25. Centers for Disease Control and Prevention (CDC). Parasites - Clonorchis. https://www.cdc.gov/parasites/clonorchis/health_professionals/index.html. Updated May 20, 2020i. Accessed February 19, 2024.
  26. Centers for Disease Control and Prevention (CDC). Parasites - Echinococcosis. https://www.cdc.gov/parasites/echinococcosis/health_professionals/index.html. Updated May 21, 2020e. Accessed March 1, 2024.
  27. Centers for Disease Control and Prevention (CDC). Parasites - Enterobiasis (also known as pinworm infection). https://www.cdc.gov/parasites/pinworm/health_professionals/index.html. Updated August 28, 2019c. Accessed October 2, 2023.
  28. Centers for Disease Control and Prevention (CDC). Parasites - Gnathostomiasis (Gnathostoma infection). https://www.cdc.gov/parasites/gnathostoma/health_professionals/index.html. Updated October 10, 2023. Accessed March 1, 2024.
  29. Centers for Disease Control and Prevention (CDC). Parasites - Loiasis. https://www.cdc.gov/parasites/loiasis/health_professionals/index.html. Updated November 24, 2020f. Accessed October 2, 2023.
  30. Centers for Disease Control and Prevention (CDC). Parasites - Opisthorchis infection. https://www.cdc.gov/parasites/opisthorchis/health_professionals/index.html. Updated May 26, 2020c. Accessed February 19, 2024.
  31. Centers for Disease Control and Prevention (CDC). Clinical treatment of taeniasis. https://www.cdc.gov/taeniasis/hcp/clinical-care/. Updated May 3, 2024. Accessed June 17, 2024.
  32. Centers for Disease Control and Prevention (CDC). Parasites - Toxocariasis (also known as roundworm infection). https://www.cdc.gov/parasites/toxocariasis/health_professionals/index.html. Updated May 26, 2020g. Accessed March 5, 2024.
  33. Centers for Disease Control and Prevention (CDC). Parasites - Trichinellosis (also known as Trichinosis). https://www.cdc.gov/parasites/trichinellosis/health_professionals/index.html. Updated May 26, 2020h. Accessed October 2, 2023.
  34. Centers for Disease Control and Prevention (CDC). Parasites - Trichuriasis (also known as Whipworm infection). https://www.cdc.gov/parasites/whipworm/health_professionals/index.html. Updated August 28, 2019c. Accessed March 6, 2024.
  35. Centers for Disease Control and Prevention (CDC). Parasites - Zoonotic hookworm. https://www.cdc.gov/parasites/zoonotichookworm/health_professionals/index.html. Updated May 26, 2020d. Accessed October 2, 2023.
  36. Conterno LO, Turchi MD, Corrêa I, Monteiro de Barros Almeida RA. Anthelmintic drugs for treating ascariasis. Cochrane Database Syst Rev. 2020;4(4):CD010599. doi:10.1002/14651858.CD010599.pub2 [PubMed 32289194]
  37. Costa SF, Weiss LM. Drug treatment of microsporidiosis. Drug Resist Updat. 2000;3(6):384-399. doi:10.1054/drup.2000.0174 [PubMed 11498405]
  38. Del Brutto OH, Roos KL, Coffey CS, et al, “Meta-Analysis: Cysticidal Drugs for Neurocysticercosis: Albendazole and Praziquantel,” Ann Intern Med, 2006, 145(1):43-51. [PubMed 16818928]
  39. de Silva N, Guyatt H, and Bundy D, “Anthelmintics. A Comparative Review of Their Clinical Pharmacology,” Drugs, 1997, 53(5):769-88. [PubMed 9129865]
  40. Drugs for Parasitic Infections. Med Lett Drugs Ther. 2013. 11(suppl):e1-e31.
  41. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  42. Frazier M, Anderson ML, Sophocleous S. Treatment of ocular toxocariasis with albendezole: a case report. Optometry. 2009;80(4):175-180. [PubMed 19329060]
  43. Garcia HH, Gilman RH, Horton J, et al, “Albendazole therapy for neurocysticercosis: A Prospective Double-Blind Trial Comparing 7 Versus 14 Days of Treatment,” Neurology, 1997, 48(5):1421-7. [PubMed 9153484]
  44. Garcia HH, Gonzales I, Lescano AG, et al; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687-695. doi: 10.1016/S1473-3099(14)70779-0. [PubMed 24999157]
  45. Garcia HH, Pretell EJ, Gilman RH, “A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis,” N Engl J Med, 2004, 350(3):249-58. [PubMed 14724304]
  46. Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev. 2001;14(1):114-128. doi:10.1128/CMR.14.1.114-128.2001 [PubMed 11148005]
  47. Gavin PJ, Kazacos KR, Tan TQ, et al. Neural larva migrans caused by the raccoon roundworm Baylisascaris procyonis. Pediatr Infect Dis J. 2002;21(10):971-975. doi:10.1097/00006454-200210000-00017 [PubMed 12394823]
  48. Goldman-Yassen AE, Derman A, Madan RP, Radmanesh A. A worm's tale or why to avoid the raccoon latrine: a case of Baylisascaris procyonis meningoencephalitis. Case Rep Radiol. 2022;2022:5199863. doi:10.1155/2022/5199863 [PubMed 36046372]
  49. Gottstein B, Pozio E, Nöckler K. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev. 2009;22(1):127-145. doi:10.1128/CMR.00026-08 [PubMed 19136437]
  50. Graeff-Teixeira C, Morassutti AL, Kazacos KR. Update on Baylisascariasis, a Highly Pathogenic Zoonotic Infection. Clin Microbiol Rev. 2016;29(2):375-399. [PubMed 26960940]
  51. Gul M, Younis I, Rathinavelu B, et al. Management of hydatid cysts in pregnancy: a report of two cases and a review of literature. Cureus. 2023;15(10):e46425. doi:10.7759/cureus.46425 [PubMed 37927757]
  52. Gyorkos TW, St-Denis K. Systematic review of exposure to albendazole or mebendazole during pregnancy and effects on maternal and child outcomes, with particular reference to exposure in the first trimester. Int J Parasitol. 2019;49(7):541-554. [PubMed 31071321]
  53. Hajek J, Yau Y, Kertes P, et al. A child with raccoon roundworm meningoencephalitis: A pathogen emerging in your own backyard?. Can J Infect Dis Med Microbiol. 2009;20(4):e177-e180. doi:10.1155/2009/304625 [PubMed 21119798]
  54. Han B, Pan G, Weiss LM. Microsporidiosis in humans. Clin Microbiol Rev. 2021;34(4):e0001020. doi:10.1128/CMR.00010-20 [PubMed 34190570]
  55. Hawk MW, Shahlaie K, Kim KD, and Theis JH, “Neurocysticercosis: A Review,” Surg Neurol, 2005, 63(2):123-32. [PubMed 15680651]
  56. Herman JS, Chiodini PL. Gnathostomiasis, another emerging imported disease. Clin Microbiol Rev. 2009;22(3):484-492. doi:10.1128/CMR.00003-09 [PubMed 19597010]
  57. Jagota SC. Albendazole, a broad-spectrum anthelmintic, in the treatment of intestinal nematode and cestode infection: a multicenter study in 480 patients. Clin Ther. 1986;8(2):226-231. [PubMed 3516398]
  58. Jee D, Kim KS, Lee WK, Kim W, Jeon S. Clinical features of ocular toxocariasis in adult Korean patients. Ocul Immunol Inflamm. 2016;24(2):207-216. doi: 10.3109/09273948.2014.994783. [PubMed 25564736]
  59. Jung H, Sanchez M, Gonzalez-Astiazaran A, et al, “Clinical Pharmacokinetics of Albendazole in Children With Neurocysticercosis,” Am J Ther, 1997, 4(1):23-6. [PubMed 10423586]
  60. Karabay O, Tamer A, Gunduz H, Kayas D, Arinc H, Celebi H. Albendazole versus metronidazole treatment of adult giardiasis: an open randomized clinical study. World J Gastroenterol. 2004;10(8):1215-1217. doi: 10.3748/wjg.v10.i8.1215. [PubMed 15069729]
  61. Kasher C, Grossman T, Vainer J, et al. First case of imported capillaria philippinensis in Israel. J Travel Med. 2022;29(1):taab132. doi:10.1093/jtm/taab132 [PubMed 34490463]
  62. Kraivichian P, Kulkumthorn M, Yingyourd P, Akarabovorn P, Paireepai CC. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg. 1992;86(4):418-421. doi:10.1016/0035-9203(92)90248-b [PubMed 1440822]
  63. La Hoz RM, Morris MI; AST Infectious Diseases Community of Practice. Intestinal parasites including cryptosporidium, cyclospora, giardia, and microsporidia, entamoeba histolytica, strongyloides, schistosomiasis, and echinococcus: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13618. doi: 10.1111/ctr.13618. [PubMed 31145496]
  64. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol. 1988;34(3):315-317. [PubMed 3396623]
  65. Lau R, Chris RB, Phuong MS, et al. Treatment of soil-transmitted helminth infections in pregnancy: a systematic review and meta-analysis of maternal outcomes. J Travel Med. 2020;27(2). doi:10.1093/jtm/taz079 [PubMed 31641774]
  66. Leder K, Weller PF. Enterobiasis (pinworm) and trichuriasis (whipworm). Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 11, 2025.
  67. Leder K, Weller PF. Liver flukes: clonorchis, opisthorchis, and metorchis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed June 17, 2024b.
  68. Leder K, Weller PF. Microsporidiosis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed March 5, 2024c.
  69. Leder K, Weller PF, Reddy DN. Ascariasis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed February 29, 2024a.
  70. Liu LX and Weller PF, “Antiparasitic Drugs,” N Engl J Med, 1996, 334(18):1178-84. [PubMed 8602186]
  71. Llanos O, Lee S, Salinas JL, Sanchez R. A 28-year-old pregnant woman with a lung abscess and complicated pleural effusion. Chest. 2020;158(5):e233-e236. doi:10.1016/j.chest.2020.07.008 [PubMed 33160543]
  72. Lo Re V 3rd, Gluckman SJ. Eosinophilic meningitis. Am J Med. 2003;114(3):217-223. doi:10.1016/s0002-9343(02)01495-x [PubMed 12637136]
  73. Matamoros G, Sánchez A, Gabrie JA, et al. Efficacy and safety of albendazole and high-dose ivermectin coadministration in school-aged children infected with trichuris trichiura in Honduras: a randomized controlled trial. Clin Infect Dis. 2021;73(7):1203-1210. doi:10.1093/cid/ciab365 [PubMed 33906234]
  74. Misra PK, Pande NK, Jagota SC. Albendazole in the treatment of intestinal helminthiasis in children. Curr Med Res Opin. 1985;9(8):516-519. doi:10.1185/03007998509109627 [PubMed 4028809]
  75. Mofid LS, Casapía M, Aguilar E, et al. A double-blind randomized controlled trial of maternal postpartum deworming to improve infant weight gain in the Peruvian Amazon. PLoS Negl Trop Dis. 2017;11(1):e0005098. [PubMed 28056024]
  76. Montresor A, Awasthi S, Crompton DW. Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop. 2003;86(2-3):223-232. doi:10.1016/s0001-706x(03)00042-1 [PubMed 12745139]
  77. Mørch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect. 2008;56(4):268-273. doi:10.1016/j.jinf.2008.01.013 [PubMed 18328567]
  78. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ. 2017;358:j4307. doi:10.1136/bmj.j4307 [PubMed 28947636]
  79. Murray WJ, Kazacos KR. Raccoon roundworm encephalitis. Clin Infect Dis. 2004;39(10):1484-1492. [PubMed 15546085]
  80. Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetsuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health. 2000;31(2):374-377. [PubMed 11127342]
  81. Nontasut P, Claesson BA, Dekumyoy P, Pakdee W, Chullawichit S. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health. 2005;36(3):650-652. [PubMed 16124432]
  82. Ochoa D, Saiz-Rodríguez M, González-Rojano E, et al. High-fat breakfast increases bioavailability of albendazole compared to low-fat breakfast: single-dose study in healthy subjects. Front Pharmacol. 2021;12:664465. doi:10.3389/fphar.2021.664465 [PubMed 33935787]
  83. Okumura N, Yamamoto K, Ohmagari N. Relapse of toxocariasis after completion of four-week treatment with albendazole. J Infect Chemother. 2024;30(8):796-799. doi:10.1016/j.jiac.2024.01.010 [PubMed 38242286]
  84. Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, Bégué RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. Emerg Infect Dis. 2007;13(6):928-930. [PubMed 17553240]
  85. Pallua K, Putz G, Mitterschiffthaler G, Brezinka C, Biebl M, Paal P. Management of hepatic echinococcosis in pregnancy. Int J Gynaecol Obstet. 2010;109(2):162. [PubMed 20176353]
  86. Pan American Health Organization (PAHO). Guideline for the preventive chemotherapy for the control of Taenia solium Taeniasis. https://iris.paho.org/bitstream/handle/10665.2/54800/9789275123720_eng.pdf?sequence=1&isAllowed=y. Updated September 2021. Accessed August 31, 2022.
  87. Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (Baylisascaris procyonis) encephalitis: case report and field investigation. Pediatrics. 2000;106(4):E56. [PubMed 11015551]
  88. Patel C, Coulibaly JT, Hofmann D, N'Gbesso Y, Hattendorf J, Keiser J. Efficacy and safety of albendazole in hookworm-infected preschool-aged children, school-aged children, and adults in Côte d'Ivoire: a phase 2 randomized, controlled dose-finding trial. Clin Infect Dis. 2021;73(2):e494-e502. doi:10.1093/cid/ciaa989 [PubMed 32668456]
  89. Persichino JG, Miller LG. Pregnancy screening and monitoring of albendazole therapy for neurocysticercosis. Clin Infect Dis. 2018;67(11):1797-1798. [PubMed 29790912]
  90. Peters JM, Madhavan VL, Kazacos KR, Husson RN, Dangoudoubiyam S, Soul JS. Good outcome with early empiric treatment of neural larva migrans due to Baylisascaris procyonis. Pediatrics. 2012;129(3):e806-811. [PubMed 22311989]
  91. Refer to manufacturer's labeling.
  92. Ramirez-Avila L, Slome S, Schuster FL, et al. Eosinophilic meningitis due to angiostrongylus and gnathostoma species. Clin Infect Dis. 2009;48(3):322-327. doi:10.1086/595852 [PubMed 19123863]
  93. Şahin Ö, Tolunay HE, Varlı EN, Arat Ö, Aydın M. Retrospective evaluation of hydatid cyst cases during pregnancy. Yale J Biol Med. 2021;94(2):271-275. [PubMed 34211347]
  94. Salam RA, Das JK, Bhutta ZA. Effect of mass deworming with antihelminthics for soil-transmitted helminths during pregnancy. Cochrane Database Syst Rev. 2021;5(5):CD005547. doi:10.1002/14651858.CD005547.pub4 [PubMed 33998661]
  95. Sawamura R, Fernandes MI, Peres LC, et al. Hepatic capillariasis in children: report of 3 cases in Brazil. Am J Trop Med Hyg. 1999;61(4):642-647. [PubMed 10548302]
  96. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80. doi:10.1093/cid/cix669 [PubMed 29053792]
  97. Siddalingappa K, Murthy SC, Herakal K, Kusuma MR. Cutaneous larva migrans in early infancy. Indian J Dermatol. 2015;60(5):522. doi:10.4103/0019-5154.164436 [PubMed 26538729]
  98. Siddiqui B, Faridi SH, Arif SH, Aslam M. Primary hydatid disease of the breast clinically masquerading as a galactocele: a case report. J Transl Int Med. 2015;3(2):82-84. [PubMed 27847893]
  99. Smego, RA, Bhatti S, Khaliq AA, et al, “Percutaneous Aspiration-Injection-Reaspiration Drainage Plus Albendazole or Mebendazole for Hepatic Cystic Echinococcosis: A Meta-Analysis,” Clin Infect Dis, 2003, 37(8):1073-83. [PubMed 14523772]
  100. Soukhathammavong P, Sayasone S, Harimanana AN, et al. Three cases of intestinal capillariasis in Lao People's Democratic Republic. Am J Trop Med Hyg. 2008;79(5):735-738. [PubMed 18981514]
  101. Steinmann P, Utzinger J, Du ZW, et al. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial. PLoS One. 2011;6(9):e25003. doi: 10.1371/journal.pone.0025003. [PubMed 21980373]
  102. Tekely E, Szostakiewicz B, Wawrzycki B, et al. Cutaneous larva migrans syndrome: a case report. Postepy Dermatol Alergol. 2013;30(2):119-121. doi:10.5114/pdia.2013.34164 [PubMed 24278060]
  103. Tianyi FL, Agbor VN, Kadia BM, Dimala CA. An unusual case of extensive truncal cutaneous larva migrans in a Cameroonian baby: a case report. J Med Case Rep. 2018;12(1):270. doi:10.1186/s13256-018-1792-y [PubMed 30231902]
  104. Tremoulet AH, Avila-Aquero ML, Paris MM, Canas-Coto A, Ulloa-Gutierrez R, Faingezicht I. Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children. Pediatr Inf Dis J. 2004;23(10):915-918. [PubMed 15602190]
  105. US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new. Accessed March 8, 2024.
  106. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new. Updated September 14, 2023. Accessed October 2, 2023.
  107. Vasantha PL, Girish N, Leela KS. Human intestinal capillariasis: a rare case report from non-endemic area (Andhra Pradesh, India). Indian J Med Microbiol. 2012;30(2):236-239. doi:10.4103/0255-0857.96708 [PubMed 22664447]
  108. Veraldi S, Rizzitelli G. Effectiveness of a new therapeutic regimen with albendazole in cutaneous larva migrans. Eur J Dermatol. 1999;9(5):352-353. [PubMed 10417435]
  109. Weller PF, Leder K. Toxocariasis: visceral and ocular larva migrans. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed May 17, 2024.
  110. White AC Jr. Cysticercosis: treatment. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed May 17, 2024.
  111. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66(8):e49-e75. doi: 10.1093/cid/cix1084. [PubMed 29481580]
  112. White AC Jr, Coyle CM, Rajshekhar V, et al. Reply to Garg et al, Smith et al, and Persichino and Miller. Clin Infect Dis. 2018;67(11):1798. [PubMed 29790917]
  113. Wilson ME, Lorente CA, Allen JE, et al, “Gongylonema Infection of the Mouth in a Resident of Cambridge, Massachusetts,” Clin Infect Dis, 2001, 32(9):1378-80. [PubMed 11303277]
  114. World Health Organization (WHO). Action against worms No 8: deworming young children. 2007. Available at https://www.who.int/publications/i/item/WHO-HTM-NTD-PCT-2007.3
  115. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435.
  116. World Health Organization (WHO). Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017. Available at https://www.who.int/publications/i/item/9789241550116.
  117. World Health Organization (WHO). Report of the informal consultation on hookworm infection and anaemia in girls and women. 1996. Available at https://www.who.int/publications/i/item/pntd-0000291.
  118. World Health Organization (WHO). WHO guidelines on management of Taenia solium neurocysticercosis. Geneva: World Health Organization; 2021. [PubMed 34520139]
  119. World Health Organization (WHO). WHO Model Formulary for Children. 2010.
  120. Yereli K, Balcioğlu IC, Ertan P, et al, "Albendazole as an Alternative Therapeutic Agent for Childhood Giardiasis in Turkey," Clin Microbiol Infect, 2004, 10(6):527-9. [PubMed 15191380]
  121. Zhang B, Wei L, Ma L. A case of cutaneous larva migrans. Int J Infect Dis. 2019;83:44-45. doi:10.1016/j.ijid.2019.04.003 [PubMed 30959248]
  122. Ziem JB, Kettenis IM, Bayita A, et al, "The Short-Term Impact of Albendazole Treatment on Oesophagostomum bifurcum and Hookworm Infections in Northern Ghana," Ann Trop Med Parasitol, 2004, 98(4):385-90. [PubMed 15228719]
Topic 13269 Version 267.0